CDNF in Amyotrophic Lateral Sclerosis
Herantis has early preclinical data suggesting possible benefits of CDNF in the treatment of ALS (Amyotrophic Lateral Sclerosis). ALS, also known as Motor Neurone Disease or Lou Gehrig’s disease, is a fatal motoneuron disease whose symptom is typically weakness of limb muscles. With disease progression the patient loses ability to control muscles causing difficulty in moving, speaking, swallowing and breathing. Average lifetime expectation from diagnosis is between two and five years. ALS cannot be cured and available treatments are essentially symptomatic. Estimated 140,000 new cases are diagnosed annually.
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application of Herantis for orphan drug designation of CDNF for treatment of ALS.